WHAT The team of parents, genetic and translational medicine scientists and pediatric oncologists trailblazing personalized medicine in the treatment of deadly pediatric cancers is convening in Austin to discuss the status of the world’s first personalized medicine clinical trial for pediatric cancer and plan next steps at the NMTRC Symposium 2012. Neuroblastoma affects 1 in 100,000 children and is responsible for 1 in 7 pediatric cancer deaths.
WHO Parents, advocates, oncologists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and biomedical researchers from the Translational Genomics Research Institute (TGen), who are using high performance computing and cloud technology from Dell to identify targeted treatments based on the specific genetic vulnerabilities of each child’s tumor—an approach that could be used to treat all pediatric and adult cancers in the future.
WHY Personalized medicine—treatment based on the specific vulnerabilities of each tumor— is overcoming longstanding barriers to treatment of pediatric cancer. There has been only one new treatment for pediatric cancer approved by the FDA since the 1980s, compared to 50 treatments approved for adult cancer in this same timeframe. As a result, pediatric oncologists use treatments designed for adults to treat children, with toxic side effects that are frequently as physically detrimental to the child as the cancer itself.WHEN The following events will be available via live-stream:May 16 1-2 pm CT: Keynote: “Molecular-Profiling for Optimized Precision Therapy, ” Dr. Timothy Triche, University of Southern California/ Children’s Hospital Los Angeles 2-4 pm CT: Panel Discussion: “Kids Cloud: Access to Data Boundaries” Dr. Melinda Merchant - National Cancer Institute Dr. Gary Marchant - Arizona State UniversityNancy Goodman - Kids V. Cancer FoundationPatrick Lacey - Friends of Will FoundationAndy Mikulak - Max’s Ring of Fire Foundation Dr. Giselle Sholler - Van Andel Institute Dr. Spyro Mousses - Translational Genomics Research Institute Dr. James Coffin - Dell WHERE Participate and join the conversation via the #HealthCloud hashtag on Twitter.Tune in via Live-Stream here: http://www.fittotweet.com/live/nmtrc/.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV